Initiates Coverage on OncoCyte (NASDAQ:OCX) began coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report report published on Friday. The firm issued a sell rating on the stock. OCX has been the subject of several other reports. Benchmark dropped their target price on shares of OncoCyte from $9.00 to $5.00 and set a speculative buy […]

Leave a Reply

Your email address will not be published.

Previous post Datadog (NASDAQ:DDOG) Stock Rating Lowered by Wells Fargo & Company
Next post Orioles’ Adley Rutschman, Ryan Mountcastle, Austin Hays named Gold Glove Award finalists